米拉贝隆：治疗膀胱过度活动症的新选择。
Mirabegron: A new option in treating overactive bladder.
作者信息
Turpen Heidi Camus, Zimmern Philippe E
机构信息
Heidi Camus Turpen practices at the University of Texas Southwestern Medical Center in Dallas, Tex. Philippe E. Zimmern is a professor of urology at the University of Texas Southwestern Medical Center. The authors have disclosed no potential conflicts of interest, financial or otherwise.
出版信息
JAAPA. 2015 Nov;28(11):16, 18. doi: 10.1097/01.JAA.0000472558.50124.7e.
Antimuscarinic medications have long been the mainstay of drug treatment for overactive bladder. This article describes mirabegron, one of a new class of agents that relaxes the detrusor muscle directly via a beta3 adrenoceptor agonist. Mirabegron's efficacy on frequency, urgency, and urge incontinence was tested in several trials before its wide clinical introduction. However, caution is still needed as data are lacking on the drug's efficacy and safety in frail older adults and for long-term therapy.
抗毒蕈碱药物长期以来一直是治疗膀胱过度活动症的主要药物。本文介绍了米拉贝隆，它是一类新型药物中的一种，可通过β3肾上腺素能受体激动剂直接松弛逼尿肌。在广泛临床应用之前，米拉贝隆对尿频、尿急和急迫性尿失禁的疗效在多项试验中进行了测试。然而，由于缺乏该药物在体弱老年人中的疗效和安全性以及长期治疗的数据，仍需谨慎使用。
Zotero 插件